Please assess the completion status of the following clinical trial:

Trial Title: Homeopathic Treatment for Depression in Peri- and Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Major depression according to DSM-IV~* Moderate to severe depression according to 17-item Hamilton Rating Scale for Depression (14-24 score)~* No current use of homeopathic treatment for depression or antidepressants or anxiolytic drugs 3 months prior to study entry~* Not be currently taking psychotherapy for at least 3 months before study entry~* Early transition to menopause defined by a change in cycle length of 7 days or longer in either direction from the participant´s own baseline for at least 2 cycles~* Late transition to menopause defined as 3 to 11 months of amenorrhea~* Postmenopausal stage defined by 12 months or more of amenorrhea~* Capability and willingness to give informed consent and to comply with the study procedures~Exclusion Criteria:~* Pregnancy or breastfeeding~* Other psychiatric disorders different from moderate to severe depression (severe depression, schizophrenia, psychotic disorders, bipolar affective disorders, suicide attempt)~* Alcohol or other substance abuse~* Known allergy to fluoxetine~* Cancer or hepatic diseases

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Individualized homeopathic treatment (Type: EXPERIMENTAL): Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
- Fluoxetine (Type: EXPERIMENTAL): Selective serotonin reuptake inhibitor.
- Placebo (Type: PLACEBO_COMPARATOR): Fluoxetine placebo plus individualized homeopathic placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).